SCHEMBL23218157

SCHEMBL23218157

COc1ccc(CC(=O)O)c(OCc2c(C)oc3ccc(-c4cc(F)cc(CN)c4)cc23)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 1/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
F11 P03951 1/20 0.38
KLKB1 P03952 1/20 0.38
F7 P08709 1/20 0.38
TPSB2 P20231 1/20 0.38
ANO1 Q5XXA6 5/20 0.38
CD274 Q9NZQ7 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
GAA P10253 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LCK P06239 1/20 0.36
PTGER4 P35408 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FFAR1 O14842 2/20 0.35
PPARD Q03181 1/20 0.35
CYP11B1 P15538 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591354 1.00 CFD (0.38) CFDPLGPLAUF11KLKB1
SCHEMBL23218876 0.91 TSHR (0.40) CFDANO1LMNAHTTGAA
SCHEMBL29852390 0.91 TSHR (0.40) CFDANO1LMNAHTTGAA
SCHEMBL29591349 0.89 CFD (0.51) CFDPLGPLAUF11KLKB1
SCHEMBL23218068 0.89 CFD (0.51) CFDPLGPLAUF11KLKB1
SCHEMBL23218165 0.85 CFD (0.43) CFDPLGPLAUF11KLKB1
SCHEMBL29591246 0.84 CD274 (0.46) CFDPLGPLAUF11KLKB1
SCHEMBL23218362 0.84 CD274 (0.46) CFDPLGPLAUF11KLKB1
SCHEMBL23218812 0.84 CFD (0.39) CFDANO1CD274GAAKDM4E
SCHEMBL29591899 0.84 CFD (0.39) CFDANO1CD274GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLG 421/4885PLAU 1119/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLG 89/4885PLAU 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.